GlassScriptPhysician profile
Kimberly Joyce Ha
NPI 1811318009
$5,934.59
in general payments reported to CMS, 2019-2025
44 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $635 · 2022: $940 · 2023: $1,170 · 2024: $1,734 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $953.55 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $706.40 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $491.76 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $466.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.48 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $243.80 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $196.72 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $148.77 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $145.70 | 2021-2025 | Xarelto, Spravato |
| Pfizer INC. | $127.80 | 2021-2025 | |
| Astellas Pharma US INC | $111.61 | 2021-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $111.13 | 2021-2024 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $95.61 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Phathom Pharmaceuticals, INC. | $64.22 | 2024-2025 | Voquezna |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.